MetaCap

ImmuCell (ICCC) vs Trinity Biotech (TRIB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

ImmuCell is the larger company by market cap ($99.3 million vs $5.1 million), about 19.6 times the size, while Trinity Biotech is growing revenue faster (+8.3% vs +4.3%). ImmuCell converts more of its revenue into profit, with a net margin of -3.8% versus -51.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ICCC+12.69%TRIB-7.56%
+23%+0%-23%
Oct 7, 20261 yearNov 20, 2026
ICCC+11.43%TRIB-8.97%
+19%+0%-19%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ICCC versus TRIB key metrics
MetricICCCTRIB
Share price$10.92$6.24
Market cap$99.28M$5.07M
1-day change-2.41%+13.76%
YTD return+77.56%—
1-year return+133.33%—
5-year return+18.70%—
P/E ratio (TTM)57.47—
EPS (TTM)$0.19$-60.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$27.64M$61.55M
Revenue growth (YoY)+4.34%+8.31%
Net income (latest FY)$-1.04M$-31.79M
Gross margin41.40%34.83%
Operating margin5.97%-34.38%
Net margin-3.76%-51.64%
52-week high$12.10$52.50
52-week low$4.67$4.54
Distance from 52-week high-9.75%-88.11%
Average volume13.44K13.54K
Shares outstanding9.09M813.13K
Employees73287
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ImmuCell is about 19.6 times larger than Trinity Biotech by market value ($99.28M vs $5.07M).
  • ImmuCell is more profitable, keeping -3.8 cents of every revenue dollar as net income versus -51.6 cents for Trinity Biotech.

About ImmuCell

ICCC stock →

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 73 employees

About Trinity Biotech

TRIB stock →

Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 287 employees

ICCC vs TRIB FAQ

Which is bigger, ImmuCell or Trinity Biotech?

ImmuCell (ICCC) is larger, with a market capitalization of $99.28M compared with $5.07M for Trinity Biotech (TRIB).

Are ImmuCell and Trinity Biotech in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons